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Abstract
Dendrimers have unique molecular architectures and properties that make them attractive materials for the development of
nanomedicines. Key properties such as defined architecture and a high ratio of multivalent surface moieties to molecular
volume also make these nanoscaled materials highly interesting for the development of synthetic (non-viral) vectors for
therapeutic nucleic acids. Rational development of such vectors requires the link to be made between dendrimer structure and
the morphology and physicochemistry of the respective nucleic acid complexes and, furthermore, to the biological performance
of these systems at the cellular and systemic level. The review focuses on the current understanding of the role of dendrimers in
those aspects of synthetic vector development. Dendrimer-based transfection agents have become routine tools for many
molecular and cell biologists but therapeutic delivery of nucleic acids remains a challenge.
D 2005 Elsevier B.V. All rights reserved.
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1. Gene therapy
The initial promise that the combination of
understanding of the molecular pathways of disease
and the complete human genome sequence would
yield safer and more efficient medicines and revolu-
tionise the way we treat patients, has not been fulfilled
to date. Nevertheless there is little doubt that genetic
therapies will make an important contribution to our
therapeutic armamentarium once some of the key
challenges, such as specific and efficient delivery,
have been solved. The fact that an adenoviral therapy
for direct injection into head and neck cancer has been
licensed recently in China [1] is just one indication of
this, while highly publicised reports of the risks of
some genetic therapies serve as a reminder of some of
the potential risks of this emerging therapeutic
approach [2,3].
1.1. Gene therapy strategies
The delivery of therapeutic nucleic acids (NA),
normally in the form of plasmids, but increasingly also
as smaller oligomers, remains one of the major
obstacles currently hampering the further exploitation
of genetic therapies. Specific and efficient delivery of
genetic material to diseased sites and to particular cell
populations is the challenge that is being addressed
using a variety of viral and non-viral delivery systems,
which all have distinct advantages and disadvantages
[4,5]. Compared to viral vectors the synthetic (non-
viral) systems are in general reputed to lack of
efficiency while offering flexibility and safety. How-
ever, this simplistic view ignores the fact that the
suitability of any gene delivery system will always
have to be matched with the clinical situation, the
specific disease and the chosen therapeutic strategy [6].
Nucleic acid based therapies take two conceptually
different approaches: firstly the delivery of plasmid
DNA or related constructs (e.g. [7,8]) to express the
gene of interest under the control of a suitable promoter
which will result in the increased activity of the target,
i.e. by production of a therapeutic protein. In contrast,
the expression of oligomeric genetic material such as
antisense oligonucleotides (ON), siRNA or DNAzyme
which in general will lead to a reduction of target
activity. In deciding on the appropriate genetic therapy
for a given clinical problem, key factors to be taken into
consideration include the number of genes involved in
the pathogenesis (monogenetic/polygenetic), the re-
quired duration of therapy (temporary vs. permanent),
potency of the therapeutic product, or the need for
targeting or regulation of the genetic war-head.
Clearly none of the current vector systems is able
to satisfy these potentially disparate needs and it is
therefore important to appreciate the strengths and
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weaknesses of synthetic vector systems in the
appropriate therapeutic context [9,10].
1.2. Barriers to gene delivery
The observation that free plasmid DNA is able to
transfect the skeletal muscle [11], the liver [12] or
tumour [13] when given in the appropriate way, but
will normally be degraded in the systemic circulation
[14] provides the rationale for dpackagingT of the
plasmid DNA. This packaging occurs with the help of
a delivery system which tends to compact and protect
the NA. Furthermore, the delivery system should help
to target the therapeutic nucleic acid to the desired site
of action and facilitate efficient intracellular traffick-
ing, typically to the nucleus [6].
The most common strategy employed for the
dpackagingT of DNA is based on electrostatic interac-
tion between the anionic nucleic acid and the positive
charges of the synthetic vector which will complex and
condense the NA into nanoparticles. Commonly used
classes of synthetic vectors are based on various
cationic lipids or polymers and, depending on the
synthetic vector material used, the resulting particles
have also been termed lipoplex, polyplex, or dendri-
plex, when dendrimers are being used [15] (Fig. 1).
Suspensions of such particles only tend to be
colloidally stable if the particles are charged, that is,
the cationic carrier will be present in excess to create
particles which repel one another. This positive charge
is also important because it facilitates cell adsorption
and mediates efficient endosomal uptake into cells
[16]. However, its non-specific nature is thought to
contribute to the discrepancies commonly observed
between in vivo and in vitro experiments. While
promiscuous binding may be advantageous in the
Fig. 1. Examples of synthetic vectors. Synthetic gene delivery vectors are based on a number of different, normally cationic materials which
support the packaging of the DNA into nanoparticles. The most important classes of materials are cationic polymers and cationic lipids. The
lipids are based on self-aggregating small cationic amphiphiles whereas the cationic polymers form complexes through multivalent electrostatic
interactions. The polymers have a variety of structures but overall tend to have molecular weights of 20 kDa and above; by contrast the PPI
dendrimers that our group has developed are relatively small (PPIG3, MW ~1.5 kDa).
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simplified in vitro environment it translates into
extensive non-specific binding to cells, biological
surfaces and blood components when the charged
particles are administered in vivo. This non-specific
binding is thought to modify the complexes and thus
make them less stable and difficult to target to organs
and remote sites [17,18].
Once the complexes have reached the target cells
they need to be taken up efficiently and then processed
in the appropriate fashion to allow efficient transfer
from the endosome to the cytoplasm and, finally, the
nucleus. This requires effective traversing of intracel-
lular compartments and the lack of efficiency for these
steps probably represents one of the key limitations of
synthetic gene delivery systems (Fig. 2).
2. Dendrimers
Since their conception in the late 1970s and early
1980s the unique properties of dendrimers have
spawned a whole range of new research areas ranging
from drug and gene delivery applications to process-
ing, diagnostics, and nanoengineering [19].
Fig. 2. The systemic delivery of gene medicines to organs and disease sites which are not directly accessible is particularly challenging (top
panel). In order to reach a remote target cell, in this example in a liver tumour, the synthetic vector system needs to travel in the blood stream to
the organ, and the tumour. Within the tumour the nanoparticles need to extravasate and distribute throughout the tumour interstitium to finally
reach the target cells where they need to be taken up efficiently. Current systems are invariably taken up into endosomes where they would
eventually be degraded. Therefore a mechanism that allows endosomal escape, e.g. by disruption after osmotic swelling (proton sponge) is
required. After escaping into the cytoplasm the nucleic acid (plasmid DNA) needs to gain entry into the nucleus to be able to utilise the nuclear
transcription machinery and initiate gene expression. Access to the nuclear machinery can in principle occur during cell division when the
nuclear envelope disappears through the nuclear pores which allow shuffling of suitable molecules between nucleus and cytoplasm.
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In comparison to the traditional polymers that
initiated a materials revolution in the second half of
the last century, dendrimers are relative newcomers.
Nevertheless, their special properties have made these
highly branched three dimensional macromolecules
the focus of much research over the last one to two
decades.
Dendrimers (from the Greek bdendronQ: tree, and
bmerosQ: part) consist of a central core molecule
which acts as the root from which a number of highly
branched, tree-like arms originate in an ordered and
symmetric fashion (Fig. 3).
Dendritic structures emerged from a new class of
polymers named bcascade moleculesQ, initially
reported by Vo¨gtle and his group at the end of the
1970’s [20] and developed further by Tomalia, New-
kome, and others to give rise to the larger dendritic
structures [21–24]. These hyper-branched molecules
were called bdendrimersQ or barborolsQ (from the Latin
barborQ also meaning tree, for a historical view see
review [25–32]).
Their unique molecular architecture means that
dendrimers have a number of distinctive properties
which differentiate them from other polymers; specif-
ically the gradual stepwise method of synthesis means
that they have in general a well defined size and
structure with a comparatively low polydispersity
index. Furthermore, dendrimer chemistry is quite
adaptable thus facilitating synthesis of a broad range
of molecules with different functionality. Key prop-
erties in terms of the potential use of these materials in
drug and gene delivery are defined by the high density
of terminal groups. These contribute to the molecules
surface characteristics, offer multiple attachment sites
e.g. for conjugation of drugs or targeting moieties, and
determine the molecular volume which is important
for the ability to sequester other molecules within the
core of the dendrimer.
Dendrimers lend themselves to nanoengineering of
these key properties in order to fashion materials for
applications in drug and gene delivery, imaging,
boron neutron capture therapy, but also various
Fig. 3. Dendrimer structure. The stepwise synthesis of dendrimers means that they have a well defined hierarchical structure. This hypothetical
dendrimer is based on a core with three covalent root attachment points but other common cores have di- or tetracovalent cores. The valency of
the core dictates the number of linked dendrons and the overall symmetry of the molecule. The dendrons are synthesised by covalent coupling of
the branch units. For each additional layer or generation that is being added to the structure the reaction sequence is repeated. In this case the
units have two new branching points at which additional units can be attached. (The generation count is not always consistent: normally
generation 0 refers to the core while sometimes it is used to describe the dendrimer after the first reaction cycle.) The number of branching
points, branching angles, and the length of the branching units determine to what extent each generation increases molecular volume vs. surface
area. For the higher generations the density of the terminal groups reaches a point where for steric reasons no groups can be added (starburst
effect). Dendrimers of higher generation also have a typical molecular density profile under favourable conditions; the high peripheral molecular
density establishes a steric outer shell and the lower density at the centre creates cavities which can accommodate guest molecules.
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biotechnological diagnostics and sensing functions
[22,33]. This review will give an overview of the
specific use of dendrimers in gene delivery and how it
relates to the specific properties of these materials.
2.1. Structures and synthesis
Dendrimers are generally characterised by a well
defined molecular architecture based on a stepwise
synthesis using either a divergent or a convergent
method (Fig. 4) [21,22].
The use of dendrimers in gene delivery draws on a
much more narrow range of chemical architectures,
predominantly those with a cationic net surface
charge, of which the PAMAM and PPI dendrimers
are commercially available.
The first exploration of dendrimers as molecules
for gene delivery focused on the PAMAM dendrimers
[21]. The PAMAM dendrimers are normally based on
an ethylenediamine or ammonia core with four and
three branching points, respectively [34–36]. Using a
divergent approach the molecule is built up iteratively
from the core through addition of methylacrylate
followed by amidation of the resulting ester with
ethylenediamine. Each complete reaction sequence
results in a new dfullT dendrimer generation (e.g. G3,
G4. . .) with terminal amine functionality, whereas the
intermediate dhalfT generations (e.g. G2.5, G3.5. . .)
terminate in anionic carboxylate groups (Fig. 5).
The other commercially available dendrimer with
relevance for drug and gene delivery is based on
polypropylenimine (PPI) units with butylenediamine
(DAB) used as the core molecule. The repetitive
reaction sequence involves Michael addition of
acrylonitrile to a primary amino group followed by
hydrogenation of nitrile groups to primary amino
groups [37]. These dendrimers are frequently referred
to as DAB-x, or DAB-Am-x, with x giving the
number of surface amines (Fig. 5).
The commercial availability and relative efficiency
of PAMAM and PPI dendrimers have meant that these
materials and their derivatives currently dominate the
area of gene delivery with dendritic polymers but a
number of other alternative systems have been
developed:
Phosphorous containing dendrimers (P-den-
drimers) of varying generation (G2–G5) terminated
with protonated or methylated tertiary amines were
tested as transfection agents [38]. At N/P ratios of 5:1
the larger P-dendrimers (G3–5) with protonable
amines were of a similar efficiency as linear PEI 22
kDa (ExGen 500k).
A dendrimer in which the oligonucleotide to be
delivered becomes part of an anionic dendrimer has
recently been reported [39]. The covalently attached
ODNs were protected from degradation and showed
improved uptake while still being able to hybridise
with their target.
Interestingly, DNA itself has been shown to be able
to support assembly into dendritic structures although
it is unclear whether this will have any application for
nucleic acid based therapies [40].
While the lower generation of dendrimers in general
tend not to complex DNA efficiently, PAMAMG2 can
effectively bind DNA when covalently linked to a
mesoporous silica bead (250 nm, 2.5 nm pores) [41–
43]. These systems have been shown to transfect
mammalian cells and could potentially be used to
simultaneously act as carriers for drugs encapsulated
within the porous bead.
While most dendritic polymers currently used are
based on symmetric structure with multiple branches
emanating from a central core, work by Florence and
colleagues demonstrates that this is not obligatory:
water soluble amphiphilic dendritic polylysine or
poly-ornithine peptides with a hydrophobic root (3
a-amino myristic acid) are asymmetric and have a
relatively lower charge density than PAMAM den-
drimers but can still achieve transfection [44,45].
Another polylysine dbranchT structure was syn-
thesised as an asymmetric methoxy(ethylene glycol)-
block-PLL dendrimer or a symmetric dbarbell shapedT
PLL dendrimer-block-methoxy(ethylene glycol)-
block-PLL dendrimer triblock copolymer which
efficiently condenses DNA [46,47].
Many other interesting dendrimer chemistries have
been developed and are reviewed elsewhere [48].
2.2. Physicochemical properties
Because of their molecular architecture, den-
drimers show some unique physical and chemical
properties which make them particularly interesting
for drug and gene delivery applications. Direct
comparison with linear or branched conventional
polymers is however not trivial because of the
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Fig. 4. Synthetic strategy. Synthetic strategies for dendrimers are based on two conceptually different strategies, the divergent and the
convergent approaches. Divergent approach: in the divergent method, the dendrimer is synthesised starting from the multifunctional core and
build up one monomer layer, or bgenerationQ, at the time [33]. The core molecule reacts with monomer molecules containing one reactive
group and two (or more) inactive groups. The reactive group reacts with one of the roots of the core molecule giving the first generation
dendrimer. After activation of the inactive groups at the periphery of the molecule the reaction sequence is repeated with the next generation
of monomers. The process is repeated for several generations until steric effects prevent further reactions of the end groups (starburst effect).
Convergent approach: in the convergent approach, the dendrimer is also built up layer after layer, but this time starting from the end groups
and terminating at the core [21]. Here two (or more) peripheral branch subunits are reacted with a single joining unit which has two (or more)
corresponding active sites and a distal inactive site. The reaction is a new larger branch subunit that is again reacted with a joining. When the
growing branched polymeric dendrons have reached target size they are in turn attached to a core molecule to yield the dendrimer, generally
highly symmetric.
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difficulty of changing polymer architecture without
affecting other parameters. Nevertheless, a compara-
tive study of the properties exhibited by dendrimers
and linear macromolecules of the same repeating unit
(OC6H4P(Ph)2N–PS (including both PN and PS
double bonds, and P–O and P–C single bonds)
provides an acute insight into how their molecular
features affect the structure–property relationship (i.e.
solubility of phosphorus-based dendrimers in organic
solvents, contrary to linear polymers) [49,50].
In contrast to linear polymers the intrinsic viscosity
of dendrimer solutions does not increase linearly with
mass but shows a maximum at a specific generation
[46,51]. This is likely to be because of the way in
which dendrimer shape changes with generation, i.e.
lower generations adopt a more open planar–elliptical
shape with transition to a more compact spherical
shape for higher generations. The compact shape also
reduces the likelihood of entanglement which affects
larger classical polymers.
Because of the dendrimer structure (Fig. 6) the
molecular density is theoretically highest in the
periphery of the dendrimers. This stylised picture
does not necessarily reflect the true shape and it has
been suggested that back folding of the terminal
branches towards leads to a more uniform or even
reverse density profile [52] (Fig. 6). The actual
confirmation of dendrimers in solution will ultimately
also depend on the interaction with the solvent: for
example, the PPIG3 (DAB-Am16) NMR takes on an
extended conformation in a bgoodQ solvent (chloro-
form), but a folded conformation when exposed to a
bpoorQ solvent (benzene) [53,54]. Other factors that
influence solubility and conformation include salt
conditions, changes in pH, dissolved ions [30].
The higher generation dendrimers have an bouter
shellQ of high molecular density (starburst effect) just
beneath the surface which provides a barrier that can
create a distinct microenvironment within the den-
drimer core which potentially also would allow the
encapsulation of guest molecules [55].
In nature tree-like structures have evolved to
maximise the exposed surface area, e.g. to maximise
the light exposure/number of leaves of a tree. In a
similar fashion dendritic architecture creates mole-
cules where a large proportion of the groups are
exposed at the surface and which can have very
high molecular surface to volume ratios (up to
1000 m2 g 1) [49]. The presence of numerous
terminal groups in dendrimers facilitates multiple
simultaneous interactions of surface groups with the
solvent, surfaces or other molecules and, as a
consequence, dendrimers tend to show high solubility,
reactivity, and binding [56].
This multivalency is of general importance for
biological interactions but may be of particular
importance for biomedical applications, as the multi-
meric binding through statistical and/or cooperative
effects can increase affinity, avidity and specificity of
binding [57]. The multiple interactions between
surface amines and nucleic aid phosphates are also
important for the formation of dendrimers and DNA
complexes (vide infra).
Furthermore, the multiple surfaces groups can be
derivatised simultaneously with a number of groups to
modify properties, for example targeting ligands or
hydrophilic copolymers (PEG) for steric stabilisation.
2.3. Biological properties
When considering the general biocompatibility of
dendrimer-based gene delivery systems, one needs to
be careful to distinguish between interactions and
effects of the free dendrimer and those related to the
Fig. 5. Synthesis of commercially available dendrimers. PAMAM dendrimer (top panel). The PAMAM dendrimers are normally based on an
ethylenediamine or ammonia core with four and three branching points, respectively [149]. Using a divergent approach the molecule is built up
iteratively from the core through addition of methylacrylate followed by amidation of the resulting ester with ethylenediamine. Each complete
reaction sequence results in a new dfullT dendrimer generation (e.g. G3, G4. . .) with terminal amine functionality, whereas the intermediate dhalfT
generations (e.g. G2.5, G3.5. . .) terminate in anionic carboxylate groups. PAMAM dendrimer structure (middle panel). The well defined
structure of dendrimers means that their properties are not statistical but can be calculated using straightforward formulas based on known
parameters such as core root points, branching units structure and number of generations [34–36]. PPI dendrimer (bottom panel). The other
commercially available dendrimer with relevance for drug and gene delivery is based on polypropylenimine (PPI) units with butylenediamine
(DAB) used as the core molecule. The repetitive reaction sequence involves Michael addition of acrylonitrile to a primary amino group followed
by hydrogenation of nitrile groups to primary amino groups [87]. These dendrimers are frequently referred to as DAB-x, or DAB-Am-x, with x
giving the number of surface amines; depending on the source DAB-Am4 is sometimes referred to as G0 or G1.
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delivery system as a whole, i.e. when the dendrimer is
part of a supramolecular assembly. When used to
deliver NA based therapeutic, molecules dendrimers
are typically part of a supramolecular assembly, i.e.
nanoparticles. The biological properties of such
supramolecular structures may differ considerably
from that of the free molecule. In general, complex-
ation with DNA tends to reduce toxicity but partic-
ulate materials may show distinct biodistribution or
cellular trafficking characteristics which can create
unique effects with a different toxicity profile.
2.3.1. In vitro
The initial evaluation of biological properties of
PAMAM dendrimer in vitro found them to be
relatively non-toxic [58]. In cytotoxicity assays they
compare favourably with some of the other transfec-
tion agents, in particular cationic polymers of higher
molecular weight such as PEI (600–1000 kDa), PLL
(36.6 kDa), or DEAE–dextran (500 kDa) which in
these assays are around 3 orders of magnitude more
toxic [58]. In contrast to the large MW PEI and PLL
polymers, PAMAM dendrimer toxicity did not seem to
stem from membrane damage as assayed by LDH
release or haemolysis [59]. Nevertheless, dendrimers
interact effectively with cell membranes and the
electrostatic interactions of cationic polymer and
anionic cell surfaces are highly important for the
cellular uptake of charged DNA complexes [60].
Studies of membrane interactions of PAMAM den-
drimers with DMPC/DMPA vesicles suggested that
vesicles can in fact wrap around larger dendrimers
[61]. Membrane interactions are thought to be impor-
tant for toxicity because of the direct damage to the
target cells but, furthermore, such interactions may
also pose a problem on systemic injection when
erythrocyte lysis or aggregation could lead to toxicity.
Size is a key determinant of dendrimer cytotoxicity
for both PAMAM [62] and PPI dendrimers [63,64].
Cytotoxicity of PAMAM dendrimers increases with
generation, independent of surface charge, for both
full generation cationic dendrimers (G2–G4) and the
dhalf-generationT anionic intermediates (G2.5, G3.5)
[64,65].
The nature and density of charged groups are other
factors that determine dendrimer toxicity [66]. Cation-
ic (surface) charges are in general more toxic but
details depend on the specific groups involved, that is,
for amines it has been proposed that primary amines
are relatively more toxic than secondary or tertiary
Fig. 6. Dendrimer conformation. The equilibrium between structures with dense shell vs. dense core depends on dendrimer chemistry and
solvent properties (polarity, pH, salt, etc.); back-folding of peripheral groups into the centre modifies molecular density away from the outer
shell and leads to a more even distribution of molecular density or a ddense coreT dendrimer structure.
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amines. A concentration dependent tendency to cause
haemolysis and changes in erythrocyte morphology
has been linked to the presence of –NH2 groups [66].
In contrast to PAMAM dendrimers PPI dendrimers
with DAB and DAE cores did not show generation
dependence for the haemolytic effect. In general
dendrimers were found to interact significantly less
with erythrocytes than PEI but were nevertheless hae-
molytic at concentrations above 1 mg mL1 [67–70].
Quaternisation has previously been used as a
strategy to reduce toxicity of polymers [71]. The
approach also seems to be beneficial for higher
generation PPI dendrimers but for complexes the
effects of quaternisation are complex and can include
changes of complex morphology and physical chem-
istry which are difficult to deconvolute [72].
By contrast anionic dendrimers, e.g. those bearing
a carboxylate surface, have been reported to be non-
cytotoxic over a broad concentration range [64],
although even for anionic dendrimers (e.g. dhalfT
generation PAMAM) a correlation exists between
toxicity and molecular weight [73].
Shielding of surface groups has also been used
successfully to reduce toxicity e.g. through covalent
attachment of C12 lauroyl groups or PEG 2000 [66].
The modification of terminal groups has been
suggested to be more efficient for higher generations
dendrimers, as the relatively higher density of non-
toxic surface groups may also be more effective in
preventing access to a potentially toxic core [72].
2.3.2. In vivo
On intravenous injection 125I labelled cationic
PAMAM dendrimers (G3, G4) are rapidly eliminated
from the circulation (around 99% in 1h) and
accumulate in the liver (more than 60%) [66]. A
similar pattern was found for the anionic dhalf-
generation PAMAM dendrimers (2.5, 3.5, 5.5),
although clearing was somewhat slower and accu-
mulation in the liver less pronounced [63]. An earlier
study by Roberts and colleagues [74] reported
kidney accumulation for PAMAMG3 and accumula-
tion in the pancreas for the PAMAMG5 and
PAMAMG7. A high level of kidney excretion was
observed for G7 but studies with PAMAM dendrimers
with varying degrees of terminal biotinilation suggest
that retention may increase with size and charge
density [75].
Clearly these observations do not necessarily hold
true for complexes made from DNA and dendrimers.
In general the toxicity of cationic polymers bound to
DNA decreases in in vitro assays but the particulate
nature of complexes is likely to have a major
influence on their biodistribution, e.g. their involve-
ment with enhanced permeation and retention effect to
target tumours [76]. Macromolecules are also
expected to be able to utilise this effect [77] which
has been exploited for the targeting of drug loaded
dendrimers [78,79].
3. Dendrimers as synthetic vectors
3.1. Dendrimer–nucleic acid interaction
The complexation process between dendrimers and
nucleic acids does not seem to differ fundamentally
from other cationic polymers with high charge
density: dendrimers interact with various forms of
nucleic acids, such as plasmid DNA or antisense
oligonucleotides, to form complexes which protect the
nucleic acid from degradation [57,78,80]. The inter-
action between dendrimer and nucleic acids is based
on electrostatic interactions [81] and lacks any
sequence specificity [80].
During the complexation the extended configura-
tion of plasmid DNA is changed and a more compact
configuration achieved, with the cationic dendrimer
amines and the anionic NA phosphate reaching local
charge neutralisation and the formation of NA–
dendrimer complexes (bdendriplexesQ).
The nature of the complex is not only dependent on
the stoichiometry and concentration of the DNA
phosphates and dendrimer amines but also on the
bulk solvent properties (e.g. pH, salt concentration,
buffer strength) and even the dynamics of mixing.
High ionic strength, i.e. increased amounts of NaCl,
interferes with the binding process [82] but also
appears to help to establish equilibrium [83,84]. The
medium in which complexes are formed not only
affects their morphology but also modifies other
properties and even stability in vivo (e.g. PEI [80]).
PAMAM dendrimers bind DNA at a 1:1 stoichi-
ometry of primary amine to phosphate [85,86] but
these dendrimer to DNA ratios are not necessarily
ideal; as with other polymeric systems, more stable
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and efficient complexes tend to be formed only at
higher polymer to DNA ratios.
With each increasing dendrimer generation the
number of surface amine groups, which are most
likely to bind DNA, doubles [81]. This also affects the
nature of complexes formed by the different gener-
ations; a model for the binding of PAMAM den-
drimers to DNA has been put forward which explains
the observation of increased binding with higher
generation dendrimers (G7 vs. G4, G2) [81]. The
model postulates the presence of regions of tightly
bound DNA interspersed with dlinkerT DNA (Fig. 7).
Based on the observation of binding of EthBr to
DNA–dendrimer complexes the authors postulate that
the higher generation dendrimers achieve a higher
proportion of tightly bound DNA by dwrap aroundT of
DNA [87].
A recent study suggests that smaller dendrimers
PAMAMG2 which do not induce a dwrap aroundT may
in fact bind DNA relatively better than the larger
PAMAMG6, potentially because of the more fluid
structure of these smaller dendrimers [82].
In the same study a model is proposed to account
for the observation of distinctive phases at low,
medium, and high ratios of PAMAM dendrimer to
DNA (expressed as surface groups to DNA base pairs)
(Fig. 7). Measurable interaction with moderate DNA
stabilisation is already observed at low ratios b1. At
ratios N 1 the dendrimers and DNA form the familiar
complexes most relevant for gene delivery. Interest-
ingly a saturation of binding occurs at ratios greater
than 100 (PAMAMG2) and 200 (PAMAMG6), respec-
tively, above which a resolubilisation of the DNA by
dsalting inT occurs.
PPI dendrimers of all generations when added in
sufficient amounts form water insoluble DNA com-
plexes [82]. While the G1–G2 PPI dendrimers lead to
the formation of electroneutral complexes even at
dendrimer:DNA charge ratios N1, the higher genera-
tion dendrimers were able to produce charged soluble
complexes because of the ability to form over-
stoichiometric complexes with a net positive charge
[88]. Interestingly the authors also demonstrated that
the complexation behaviour of DNA itself differed
significantly from that of other poly-cationic poly-
mers: the flexible linear polymers (dsingle strandT)
were able to interact with all dendrimer amines
including those dinsideT the dendrimer, whereas the
more rigid DNA (ddouble strandT) was only able to
interact with surface amines [62]. This configuration
would leave a number of anionic and cationic residues
unable to interact and thus retain some charge with the
complex. Molecular modelling studies with PPI
dendrimers of G1–G5 also suggest that for generations
higher than 2–3 a significant proportion of the
dendrimer molecule would not interact directly with
the same DNA strand (Fig. 7) [62]. The PPIG1 appears
to bind across the major groove but the larger PPIG3 is
sufficiently large to bind across an entire helical turn,
spanning major as well as minor groove. In the above
model of dendrimer binding there is not necessarily a
distinction between core and surface amines for DNA
binding but, analogous to other models of DNA–
dendrimer interaction, uncomplexed groups remain in
the case of the higher generation dendrimers. This
study also supported the notion of a minimum size
requirement for optimal DNA binding, although in this
case the optimum is reached earlier than had been
suggested for PAMAM dendrimers, i.e. around G3 to
G4 [89].
With regard to the longer range arrangement of the
dendrimers along the DNA a recent X-ray diffraction
Fig. 7. Dendrimer DNA interaction. The supramolecular structures formed by dendrimers and DNA differ with dendrimer–DNA ratio. A model
that is trying to explain generation dependent differences in DNA binding suggests the existence of more loosely bound regions of DNA (dlinker
DNAT) and tighter bound DNA, with the ability to induce DNA wrap around for higher generation dendrimers (top left panel, after [81]).
Depending on the ratio of DNA and dendrimer various supramolecular aggregates of DNA and dendrimers exist. The observation of distinctive
phases of high and low solubility aggregates at low, medium, and high ratios of PAMAM dendrimer to DNA (expressed as surface groups to
DNA base pairs) can be explained as illustrated. Soluble aggregates exist at ratios below 1 (PAMAM) and at high ratios of greater than 100
(PAMAMG2) or 200 (PAMAMG6). The intermediate ratios are dominated by insoluble complexes (top right panel, after [87]). Molecular
modelling studies with the smaller PPI dendrimers (PPIG1–5) suggest different dendrimer generations interact with DNA to a varying extent: the
first generation dendrimer only binds across the major groove whereas the larger G3 binds across an entire helical turn. With increase in size a
larger proportion of the dendrimer appears not to directly interact with the neighbouring DNA (middle panel, from [62]). Longer range forces
organise the structures formed though DNA–dendrimer interaction. An X-ray diffraction based model of PPIG4 and PPIG5–DNA aggregates
shows the formation of columnar mesophases when condensed with high molecular weight DNA. The cartoons depict cross sections through
extended fibrils with square (S phase) or hexagonal (H phase) arrangement around the dendrimer core (bottom panel, after [89]).
C. Dufe`s et al. / Advanced Drug Delivery Reviews 57 (2005) 2177–22022188
C. Dufe`s et al. / Advanced Drug Delivery Reviews 57 (2005) 2177–2202 2189
study using PPIG4 and PPIG5 suggests that these
complexes form hexagonal mesophases when con-
densed with the high molecular weight DNA. These
phases show a square or hexagonal arrangement
around the dendrimer core [78,80] with a tendency to
form extended fibrils. Furthermore the exact structure
was shown to be changeable in response to changes in
ion concentration and DNA/dendrimer ratio.
Initial studies of DNA complexes formed by
PAMAM dendrimers found that their morphology
was quite similar to complexes formed with other
cationic polymers such as polylysine or polyethyleni-
mine [80]. In all cases the formation of toroidal
structures of around 50 nm was observed. Polylysine
and intact PAMAM dendrimer-based complexes, in
particular with higher generation dendrimers, were
found to have a tendency to form clusters rather than
distinct units, in contrast to those complexes observed
for the PEI and fractured PAMAM. Complex size
tended to decrease with increasing polymer:DNA
ratio for the fractured PAMAM dendrimer [71,79,90].
The morphology of PAMAM and PPI dendrimer
DNA complexes has recently elucidated further using
atomic force microscopy [91].
Interestingly there is some evidence to suggest that
at least for some of the systems there is considerable
heterogeneity among the complexes formed under
specific conditions. For a specific formulation of
PAMAMG7 DNA complexes more than 90% of
transfection resulted form only 10–20% of complexes
which were of lower density and solubility [92].
3.2. Mechanistic aspects of dendrimer transfection
In mechanistic terms it appears that dendrimers are
in fact quite comparable to other polymeric transfec-
tion agents. The specific structure of a dendrimer
influences its physicochemical properties and thus the
properties of the resulting complex, but any such
difference seems to result only in gradual (rather than
categorical) or qualitative differences between the
different formulations.
The binding of cationic DNA complexes to the cell
membrane is in general based on an initial electro-
static attraction between the cationic complex and the
negatively charged cell surface groups. The com-
plexes are then taken up by endocytosis and depend
on efficient endosomal escape mechanisms to be able
to reach the cytosol and finally the nucleus. Recent
research suggests that binding and uptake of den-
drimer (Superfectk) depend on cholesterol [93], as
had been reported for lipoplexes [94].
The G6 and G7 PAMAM dendrimers are highly
effective in inducing leaky fusion of model vesicles
probably by induction of an inverted hexagonal phase
[95]. This tendency for strong interaction with
membranes was confirmed in fibroblasts; PAMAM
dendrimer binding to single fibroblasts was quantified
using confocal microscopy and was found to correlate
with dendrimer generation [96]. A recent report
suggests that the dendrimers interact with artificial
and cellular membranes in a way that facilitates
formation of small (15–40 nm), transient pores
[61,97,98]. This effect was dependent on cationic
dendrimer surface groups and correlated with charge
density, that is, the PAMAMG7 was found to be
significantly more active than the PAMAMG5.
There is now good evidence supporting the impor-
tance of dendrimer buffering capacity to act as a dproton
spongeT and facilitate efficient endosome disruption
[98]. The high buffering capacity of polymers such as
PEI and PAMAM leads to a decelerated acidification of
the endosome, an increased accumulation of osmoti-
cally active Cl, and induces a 140% increase in
endosome volume [99,100].
The notion that the amount of dendrimer is not
only important in creating the excess positive charge
which supports cellular association and uptake but
also for the intracellular trafficking process is also
supported by data for cyclodextrin–dendrimer com-
plexes [101]. Here it was shown that cellular
association depends on excess positive charge, but,
while the optimum of transfection was achieved with
higher charge ratios of 200:1 maximum cellular
association was already reached at ratios of around
5:1.
The transfer from the cytoplasm to the nucleus is a
critical step in the transfection process. Fluorescence
microscopy of dendrimer–AS complexes (Oregon
green conjugated PAMAMG5 and TAMRA labelled
AS oligonucleotide) suggests that the dendrimer itself
has the ability to accumulate to some extent in the
nucleus [102] similarly as it has been described for
PEI [103].
One intriguing difference between polymeric and
lipidic delivery systems seems to lie in their intracel-
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lular processing. While for lipid based systems
dissociation of the complex at the level of the
endosome seems to be obligatory, this does not
necessarily hold true for polymeric systems which
appear to have at least some activity even when still
complexed. Specifically PAMAMG5 dendrimer anti-
sense ON complexes seemed to be active although a
large proportion of AS in the nucleus seemed to be
still complexed [78]. However, an early study
suggested that PAMAM dendrimers would inhibit
the initiation of transcription in vitro but not affect the
elongation of the RNA transcript [104].
3.3. Dendrimers as cellular transfection agents
The first report of the use of Starburstk PAMAM
dendrimers as transfection agents demonstrated that
these agents could efficiently induce expression of
reporter genes in adherent and suspension cell cultures
with the G6 (NH3) dendrimer having optimum
efficiency [104]. Relatively small dendrimer DNA
complexes with a significant excess of positive to
negative charge (6:1) were most efficient but strongly
affected by the presence of serum [104]. Interestingly
it was also demonstrated that these materials, in
contrast to poly-l-lysine, were not dependent on the
presence of lysosomotropic agents, suggesting that
they had an intrinsic ability to escape from the
endosome. The authors suggested that this ability
may be related to the ability of the dendrimer amine
groups to buffer pH changes in the endosome [104–
106]. This has been proposed as a general mechanism
that facilitates escape from the endosome because of
the accumulation of Cl and subsequent osmotic
swelling of the endosome [98]. This hypothesis has
also been supported by some recent experiments
which studied the effect of various polyamines on
endosome swelling [57].
Bielinska and colleagues then demonstrated that
the cationic PAMAM dendrimers were not only able
to complex and deliver plasmid DNA but also
antisense oligonucleotides [107]. Furthermore, they
were able to use PAMAM dendrimers to create cell
lines which constitutively express a reporter gene.
While PAMAM starburst dendrimers of generation
G3 to G10 were found to form stable complexes with
DNA their ability to transfect different cell lines
varies. Overall the higher generation dendrimers (G5–
G10) were found to be of superior efficiency, showing
a near exponential increase of efficiency with gener-
ation in Rat2 cells [107]. In some cell lines the ability
to create stable clones was also quantified and found
to be on the order of 10 3 to 10 5. The nature of the
core, ammonia (NH3) or ethylenediamine (EDA) was
found to be less significant, highlighting the greater
importance of the surface in the nature of the complex
[108]. This may however be less clear for smaller
dendrimers where access to the core groups is
sterically less restricted. More recently a comparison
of PAMAMs derived from pentaerythritol (DP),
inositol (GI) and trimesyl (DT) core architectures
demonstrated an effect of core structure on both the
optimum dendrimer generation for condensation and
in vitro transfection, with DT having an optimum of
G6 rather G5 [109]. A molecule which resembles a
dpulled apartT PAMAM dendrimer, i.e. a barbell shape
with an extended core, was synthesised as a
PAMAM–PEG–PAMAM triblock copolymer [104].
This spatial extension of the core improved cytotox-
icity of the dendrimer and colloidal stability of the
complexes without major changes to the transfection
efficiency.
Density of groups however appears to be of
importance for the ability of PAMAM dendrimers to
transfect: difficulties in reproducing earlier results with
PAMAMG3 NH3 starburst dendrimers [110] led to the
suspicion that degradation of the polymer had contrib-
uted to its good transfection ability [110]. By heating in
solvolytic solvents dendrimers can be fractured or
activated to give dimperfectT dendrimers which have
clearly improved efficiencies with enhancements in the
order of N 50 [111]. These significant differences in
biological effect between almost identical compounds
highlight the importance of even subtle changes on
complex physicochemistry and subsequently transfec-
tion efficiency of complexes.
One of the key advantages of synthetic transfection
agents is their sequence independence and the ease with
which even large DNA constructs can be accommo-
dated. An extreme example is the successful transfec-
tion of a 60 Mb artificial mammalian chromosome into
cells using a PAMAM dendrimer (Superfectk) [112].
In a comparative evaluation of various polyplexes
based on linear, branched, and dendritic polymer
structures, Gebhart and colleagues demonstrated that
the transfection activity between these polymers
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varied by 3 orders of magnitude [112]. The authors
ranked the best agents according to their ability to
transfect a panel of cell lines. The ranking was 22 kDa
linear PEI (ExGen 500k)Nactivated PAMAM den-
drimer (Superfectk)NN25 kDa branched PEINP123-
g-PEI(2 k), a Pluronic PEI graft block copolymer.
These polymer based systems were found to be more
active than some of the commercial cationic lipid
systems [112]. However, transfection activity varied
up to 3 orders of magnitude depending on the specific
cell line. Interestingly the same study also demon-
strated that factors such as incubation time of the
complexes with the cells, or cell density will affect
different polymers to a varying degree, that is, linear
PEI 22 kDa based complexes show a cell density
dependence, while the fractionated PAMAM den-
drimer complexes (Superfectk) show some time
dependence, requiring longer incubation time [112].
A PPI dendrimer with DAB core (DAB-Am64,
Astramolk), despite the similar architecture to the
PAMAM dendrimer, appeared to be the least efficient
agent. Its application was also hampered by signs of
toxicity at higher N/P ratios [72], which had been
highlighted previously [62].
Our own observations support the notion that for
the DAB-PPI dendrimers–as for most other synthetic
transfection agents–a balance needs to be struck
between the ability to facilitate transfection and
cytotoxicity [62]. Both the ability of DAB-PPI
dendrimers to bind DNA, as well as their cytotoxicity,
are generation dependent. Physicochemical character-
isation of complexes and molecular modelling studies
support the notion that an optimal size, i.e. dendrimer
generation, for DNA binding exists which also shows
some correlation with the efficiency of transfection. In
this study the lower generations of PPI dendrimers,
specifically PPIG3 (DAB-AM16), demonstrate a
transfection capability similar to that of the cationic
lipid DOTAP [113]. More recently this dendrimer was
also shown to be able to mediate antisense transfer in
vitro at levels comparable to the commercial oligo-
nucleotide transfection agent Oligofectaminek [114].
PPI dendrimers were also shown to strongly improve
cellular delivery of ON in another study focusing on
triplex forming ON [114]. The enhancement was
reported for various cancer cell lines (MDA-MB-231
14-fold) and found to be strongest for G4
[57,101,115–117].
The ability of PAMAM dendrimers to deliver
oligonucleotides has been established previously
[115] and a PAMAMG3 dendrimer was found to
increase cellular uptake of phosphorothioate ON by a
factor of 50 compared to ON alone [118]. Yet, for
unclear reasons, the fractured PAMAMG6 (Super-
fectk) and other polymers such as PEI and PLL were
reported to not be able to enhance ON transport in
D407 and CV-1 cells [119].
4. In vivo gene expression and experimental
therapy
The ability of non-viral systems such as Super-
fectk to efficiently transfect various cells in vitro has
made synthetic vectors a routine tool in molecular
biology. Yet, they have had little impact on the
translation of genetic therapies into the clinic to date.
It remains a significant challenge to make valid
predictions on the in vivo behaviour of synthetic
vectors. When one considers the vastly increase
complexity of the system that is being introduced by
the range of possible interactions between array of
biological macromolecules and cells this is not really
surprising. The challenge can be significantly reduced
by circumventing the vascular compartment. Conse-
quently, many applications of dendrimers in vivo have
focused on their use for local or ex vivo administra-
tion. Despite of these challenges there is some
evidence that dendrimer-based delivery systems have
a significant potential for the delivery of genetic
therapies in vivo.
4.1. Localised/ex vivo administration
4.1.1. Eye
Direct application of activated PAMAM (Super-
fectk) complex ex vivo on human and rabbit corneas
resulted in 6–10% of cells being transfected (18:1
ratio) [120] and intravitreal injection of complexes
with AS–ON and a lipid lysine dendrimer inhibits
neovascularisation of the choroidea by down regula-
tion of VEGF over a period of up to 2 months [121].
4.1.2. Tumour
Intratumoural injection of 100 Ag HSV-tk suicide
vector complexed with Superfectk PAMAM den-
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drimer at a 3:1 ratio (w/w) led to a pronounced growth
delay [121]. The plasmid contained EBV sequences
with the ability to replicate and persist in the nucleus
of the transfected cells (carrying the Epstein–Barr
virus nuclear antigen, EBNA1, and oriP). The animals
received up to four weekly cycles (single injection of
complex followed by 100 mg/kg/day of the prodrug
Ganciclovir for 6 days) [122]. Measuring levels of h-
gal expression of the plasmid employing the EBNA1/
oriP system were eight times higher than in a
conventional plasmid and in conjunction with a vector
expressing Fas ligand the injection of 10 Ag plasmid
complexed with dendrimer (Superfectk) at a ratio of
10:1 (w/w) also led to a pronounced tumour growth
delay [123,124].
A growth delay was also demonstrated after
intratumoural injection of plasmids coding for the
anti-angiogenic peptide angiostatin or the tissue
inhibitor of metalloproteinase (TIMP)-2 genes in
special dendrimer/plasmid/oligonucleotide complexes
[125]. The formulation was based on a mixture of 5
Ag of plasmid, 60 Ag of activated PAMAM dendrimer
(Superfectk), and 20 Ag of a 36-mer oligonucleotide
complexing the plasmid coding for the therapeutic
gene.
Efficient local delivery of an 111In labelled ON to
tumour cells in an intraperitoneal tumour model has
been demonstrated when complexes with PAMAMG4
were injected i.p. [126].
4.1.3. Heart
Using direct injection in a murine cardiac trans-
plant model PAMAMG5 dendrimer complexes dem-
onstrated more widespread and prolonged expression
compared to the naked plasmid and when combined
with a viral interleukin 10 gene were able to prolong
graft survival [127]. The efficiency of the procedure
was improved at a higher charge ratio of 20:1 [128],
and in combination with electroporation [129].
On direct local administration to the adventitia of
the rabbit aorta Superfectk was also found to be more
efficient (4.4%) than branched PEI 25 kDa (2.8%),
branched PEI 800 kDa (1.8%), or naked DNA (0.5%)
[130].
4.1.4. Lung
Gene expression after intratracheal instillation of
complexes with fractured PAMAM dendrimer (Super-
fectk) at N/P ratio of 4.7 (32.1 Ag dendrimer/20 Ag
plasmid, 50 AL) was found to be 130-fold lower than
for the branched PEI 25 kDa formulation (N/P 10:1)
[131].
4.2. Systemic administration
Intravascular administration of complexes with
PAMAMG9 (200 Ag DNA complexed with 650 Ag
dendrimer) led to expression mainly in the lung
parenchyma but not in other organs [132].
The systemic administration of dendrimers was
also investigated for a PAMAMG3 and conjugates of
a-cyclodextrin (aCD) with the terminal amines of
PAMAMG3 [132]. After 12 h the spleen was clearly
the dominant organ and at least one order of
magnitude higher than the next highest organ, the
liver [132]. The modified dendrimer led to a shift in
the expression pattern depending on the level of
substitution and in some organs significantly im-
proved the expression [9,17,18].
The aim of our own work has been the develop-
ment of delivery systems for the systemic treatment of
diseases and specifically of solid tumours. Cancer
therapy is currently limited by the difficulty to
efficiently deliver therapeutic molecules or genes to
remote tumours and metastasis by systemic adminis-
tration [70,133,134].
We have previously developed a number of
systems suitable for in vivo delivery of genes [62].
We have reported that the lower generations of PPI
dendrimers are promising delivery systems which
strike a good balance between binding/stability and
toxicity [71]. We have demonstrated that these
systems are also potentially useful for systemic gene
therapy: PPI dendrimers of G1–4 (DAB-Am 4/8/16/
32) were characterised and compared with their
quaternised counterparts [71]. The quaternisation
improved DNA binding of lower generations and
cytotoxicity of the higher generations tested. In
particular for PPIG2 quaternisation proved advanta-
geous as it rendered the previously toxic complex
safe. In vivo the formulations based on PPIG3 (DAB-
Am16) and the quaternised PPIG2 (QDAB-Am8)
efficiently expressed transgenes predominantly in the
liver rather than the lung [135].
We have recently been able to demonstrate that an
intravenously administered gene medicine consisting
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of the PPIG3 complexes is able to induce intra-
tumoural transgene expression [135]. When murine
xenografts are treated by intravenous injection of
PPIG3 complexes with a tumour necrosis factor
(TNFa) expression plasmid under control of a tumour
specific promoter, regression of established tumours
has been observed in 100% of the animals. The
treatment (5 injections over 10 days) also led to an
excellent long-term response (at 17 weeks: 80%
complete and 20% partial response). The anti-tumour
activity is the result of synergies of the effects of the
tumour specific expression of TNFa and an intrinsic
anti-proliferative effect of the dendrimer. This novel
anti-proliferative effect was also observed with other
cationic polymers. The lack of apparent toxicity and
significant weight loss compared to untreated controls
suggest the treatment to be relatively well tolerated
and safe [107].
4.3. Complex modulation through additives and/or
conjugation
In one of the first series of experiments that
explored PAMAM dendrimers as a gene delivery
system the modulation of complexes through the
presence of other compounds during the complex
formation was described [107]. The addition of the
cationic transfection polymer DEAE–dextran to the
dendrimer–DNA complexes appears to have an
additive or possibly synergistic effect on the transfec-
tion efficiency observed with PAMAMG9 [136,137].
At concentrations of 0.25–1 AM the positive effect on
transfection was however balanced by a doubling of
cell death to 5–8% of cells.
The effect of the DEAE–dextran was ascribed to
changes in complex morphology, that is, the admix-
ture counteracted the tendency of the higher genera-
tion PAMAM dendrimers to form supramolecular
aggregates. Positive effects on the ability of com-
plexes to transfect have also been reported for the
combination of low MW PEI with high MW PEI and
various lipidic systems but do not seem to be
applicable to the fractured PAMAM dendrimer Super-
fectk [138].
The enhancement of viral transduction in the
presence of cationic lipids as well as the increase of
transfection from synthetic systems in the presence of
replication defective adenovirus has previously been
established (dadenofectionT/dlipoductionT) [139] and
has then been extended to PEI based systems [140],
and finally dendrimers [140]. In the case of addition
of synthetic systems to adenovirus the effect is
explained by an increased uptake of dendrimer/
adenovirus independent of CAR receptor status,
whereas in the case of adenovirus addition to a non-
viral transfection systems seems to increase the level
and duration of expression [141].
The combination of dendriplex with major poly-
omavirus capsid protein has been tested for the
delivery of ON and plasmid DNA [141]. Den-
drimer–DNA complexes applied in conjunction with
pentamers of the VP1 capsid were reported to have
improved transfection compared to the complex alone
[142].
Substituted cyclodextrin (CD) can enhance the
transfection efficiency of dendrimer-based complexes
[142]. The amphoteric and sulfonated h-CDs do not
complex DNA by themselves but can modulate the size
and distribution of PAMAMG5 dendrimer complexes,
particularly at relatively low N/P ratios. In this fashion
they appear to significantly enhance efficiency, specif-
ically of surface mediated transfection [99,100,132].
4.3.1. Conjugates
Covalent conjugates of CyD-dendrimer have also
been used to increase the efficiency of PAMAM
systems [99]. Only conjugates of a, h, g-CD but not
mixtures of dendrimer and CyDs were able to
significantly increase the transfection observed with
the lower generations of PAMAM dendrimers (G2–
G4) which are otherwise not able to transfect cells
efficiently. The efficiency of CyD–dendrimer mediat-
ed transfection increased with N/P charge ratio and
reached a plateau at comparatively high values of
200:1 (dcharge ratioT) with a maximum for the a-CD
conjugate [100]. With respect to the different den-
drimer generations the G3 conjugate seemed to be
superior to both the G2 and G4 conjugates [100].
Fluorescence microscopy showed that a higher
proportion of the CD conjugate complexed DNA
was delivered to the cytosol thus suggesting a
potentially increased endosomal release from the
conjugates [132]. A medium degree of substitution
(2.4 CyDs/dendrimer) was advantageous in terms of
transfection in vitro compared to a low (1.1) and high
(5.4) degree of substitution and was also able to
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induce luciferase expression in various organs after
tail vein administration. The dominant organ in the
distribution of gene expression for this conjugate was
the liver [101].
When investigating the intracellular distribution of
PAMAMG5 dendrimer–AS complexes using fluores-
cently labelled conjugates Yoo et al. discovered that
the conjugation of the small hydrophobic dye Oregon
green 488 to the dendrimer significantly increased
shuttling efficiency to a level comparable with
commercial agents [116]. It remains unclear whether
the effect of the dye is exerted through changes in the
dendrimer–AS complex physicochemistry or through
a biological effect of the conjugate e.g. an increased
interaction and disruption of endosomal membranes.
Substitution of PAMAMG4 dendrimer by conjuga-
tion of the surface amines with l-arginine was
reported recently [143]. This approach was able to
enhance transfection efficiency in several cell lines
compared to unmodified dendrimer or dendrimer
modified with terminal lysine [144].
A positive correlation of the level of substitution of
terminal amino functions of PAMAMG4 with a
hydrophobic amino acid residue (phenylalanine) and
the ability of the respective complexes to transfect
mammalian cells (CV1) was also recently reported
[144]. A fully substituted PAMAM dendrimer had
relatively low water solubility but was highly efficient
in transfection experiments [145].
The addition of the biologically inactive cucurbi-
turil, a large cage compound composed of glycoluril
units interconnected by methylene bridges, has also
been shown to modulate complex formation between
PPIG4/PPIG5–DAB dendrimer and DNA [145].
Depending on the sequence of mixing and concen-
trations, various ternary complexes with sizes between
150 and 210 nm are formed between all three
constituents that were able to transfect with similar
efficiency but reduced toxicity. The authors proposed
the non-covalent addition of dendrimer–ligand con-
jugates as a strategy for the non-covalent addition of
targeting ligands [123].
The presence of anionic oligomers such as dextran
sulphate or oligonucleotides together with plasmid
DNA during the complex formation has been dem-
onstrated to significantly influence the morphology of
complexes formed [124], although the extent of the
enhancement seems to strongly depend on the specific
conditions such as buffer and cell line [37]. Com-
plexes formed from phosphorous containing den-
drimers [123] and activated PAMAM dendrimer
(Superfectk) were significantly less dense and
appeared to be less prone to aggregation when the
anionic oligomers were used [123]. Expression levels
from complexes formed at N/P of 1.8 were the same
when from 0.5 Ag of plasmid and 3.0 Ag oligonucle-
otide as from 3.5 Ag of plasmid. Oligonucleotides of
36–55 length were found to be optimal and, similar to
a 10-mer dextran sulphate, had improved efficiency,
which was apparently linked to an increased uptake of
the less dense complexes into cells [146].
Another strategy proposed to increase transfection
efficiency from dendrimers was based on the hypo-
thesis that a conjugate of PEG (3.4 kDa) to a lower
generation PAMAM dendrimer would mimic proper-
ties of the fractured PAMAM (Superfectk). The
authors report that a PAMAMG5 conjugated in this
fashion possesses low cytotoxicity and leads to a 20-
fold increase in transfection efficiency compared to
the activated PAMAM [70,147].
4.3.2. Quaternisation
We have previously used quaternisation of water
soluble linear and branched polymers as a strategy to
modulate their physicochemistry and cytotoxicity [71]
and have recently also explored this strategy in
conjunction with PPI dendrimers [71]. The lower
generation PPI dendrimers (G1–G4) were modified to
the respective methyl quaternary ammonium deriva-
tives. In particular for the quaternisation of the PPIG2
this led to an improved DNA binding and complex
stability. This was accompanied by a dramatic
improvement of in vivo safety, that is, in contrast to
complexes formed with the unmodified dendrimer the
formulations were now well tolerated on intravenous
injection. Furthermore, the modified polymer was
able to facilitate transfection in the liver after systemic
administration. Quaternisation also increased biocom-
patibility of G3 and G4 complexes by about 4-fold but
did not affect in vitro toxicity for the lower
generations G1, G2 [68].
PAMAM–OH dendrimers do not interact suffi-
ciently with DNA to form complexes as their external
amines have been replaced with hydroxyl functions
and the internal tertiary amines have a diminished
tendency to bind DNA because of their relatively low
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pKa [68]. Quaternisation of the internal amines with
methyl iodide was used to produce PAMAM–OH
dendrimers with different levels of quaternary internal
amines (0.27–0.97) and their interaction with DNA
studied [17]. These experiments demonstrate that both
N/P charge ratio and charge density of the dendrimer
influence complex formation. Only dendrimers with a
degree of quaternisation greater than 0.78 were able to
form compact complexes and efficiently exclude
ethidium bromide. These complexes, in contrast to
those formed with PAMAMG4, had a neutral ~-
potential even at N/P ratios of 10, suggesting that
the charge interaction with DNA occurred through the
internal quaternised amines while the hydroxyl groups
at the dendrimer surface appear to have lead to a
shield of the positive complex interior at the surface.
The quaternisation of amines was found to be an
efficient strategy to modulate polymer toxicity. The
transfection capability of these dendrimers was an
order of magnitude lower than that from the cationic
PAMAMG4, which itself is not the most potent
PAMAM dendrimer. This may be predominantly
due to the lack of ~-potential which would eliminate
non-specific electrostatic binding to cell surfaces and,
consequently, is likely to have reduced uptake
dramatically. The lack of charge could conceivably
be advantageous for ligand based targeting strategies
[68]. It is the comparison of expression per internal-
ised plasmid which in this case would give a more
accurate measure of the ability of a complex to
transfect. The study also confirms the notion that
cytotoxicity of dendrimers is a function of the nature
of the amine (18, 28, 38, 48) [148].
5. Conclusion
The holy grail for the rational design of synthetic
gene delivery systems would clearly be to link
chemical structure of cationic complexation agents
to the morphology and physicochemistry of the
respective nucleic acid complexes and then to further
link this to the biological properties on a cellular and
systemic level. However, our understanding of each of
these steps is still very much incomplete and a large
proportion of research remains based on empiricism.
Conceptually the way synthetic delivery systems
are generally being developed suggests that what is
required is a relatively non-toxic cationic material
which can form a complex with DNA of a size on the
order of a few hundred nanometres which show
retardation in agarose gels, prevent binding of
ethidium bromide, and protect the DNA from degrad-
ing enzymes. The next step in general involves testing
of the ability of complexes formed at various N/P
ratios to increase reporter gene expression in a small
number of cell lines in the presence or absence of
serum components. If the system shows some activity
compared to currently used standard reagents one
would then consider testing of the system in vivo,
using reporter gene expression in various organs as
the readout.
This development strategy is being widely fol-
lowed but is probably based as much on the
availability of relatively straight forward assays as
on empirical success. Even an extension of the
analytical armamentarium does not readily create a
link between physicochemistry, i.e. the interaction
between DNA and dendrimer, and the ability of a
dendrimer to facilitate transfection [112]. The research
focus on improvement of transfection levels means
that there is probably a considerable bias against
publications which highlight this critical problem.
If one considers recent data in which a number of
polymers and dendrimers were compared in various
cell lines the picture that emerges demonstrates how
fragile the current approach can be: the differences
between the seven tested polymers were as large as
the differences seen for one of the polymers in
different cell lines, i.e. three orders of magnitude,
and the ranking of agents varied accordingly between
different cell lines but was also affected by other
factors such as e.g. cell density [22].
This variability means that it can be problematic to
compare results between in vitro studies and the
potential implication of such variability for therapeu-
tic delivery has not yet been explored; nevertheless,
dendrimer-based agents and specifically the fractured
PAMAM dendrimers (Superfectk) are clearly among
the best and most widely applicable transfection
agents and have become a standard tool for many
cell and molecular biologists.
The transition from in vitro transfection experi-
ments to in vivo studies is the logical next step in the
development of gene delivery systems, as ultimately
the aim is to use these systems to treat human disease.
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Yet one needs to remain sceptical about the extent to
which in vitro systems are currently able to predict the
ability of a formulation to bring about targeted high
level transgene expression. When one considers the
added levels of complexity in vivo, it is not surprising
that many promising developments fail to make an
impact in vivo, most commonly because of a lack of
efficacy or concerns about safety and/or toxicity.
Nonetheless, dendrimer-based delivery systems have
shown considerable promise as tools for the further
development of genetic therapies. While most of the
applications so far have focused on the use of
dendrimer-based vectors for local or ex vivo admin-
istration, our own recent work has demonstrated that
specifically PPI dendrimers may have some properties
which appear to make the particularly suited to
systemic in vivo administration. Undoubtedly the
obstacle of safe and efficient delivery of genetic
medicine largely remains significant and the suitabil-
ity of any gene delivery systems will always have to
be matched with the clinical situation, the specific
disease and the chosen therapeutic strategy.
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